The AbbVie Ventures-backed neurodegenerative disease treatment developer floated in the middle of its range having previously raised $129m in funding.

Prevail Therapeutics, a US-based gene therapy developer that counts pharmaceutical firm AbbVie as an investor, will raise $125m when it floats on the Nasdaq Global Market later today.

The offering consists of just over 17.3 million shares priced at $17.00 each, at the midpoint of its $16 to $18 range. It values the company at approximately $577m.

Founded in 2017, Prevail is working on adeno-associated virus (AAV)-based gene therapies intended to treat neurodegenerative diseases by increasing or decreasing the expression…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn